The list of upregulated genes (CDKN2A, MEX3A, RPL39L, VARS, GSPT1, SNRPE, SSR1, and TIA1) were input to breast cancer patients (2032 patients) with 997 low expressed and 1035 high-expression patients with a cut off value between highly and lowly gene expression of 521.6; colon cancer patients (1167 patients) with 748 low-expression patients and 419 high-expression patients and a cut-off value for the gene expression of 147.5; and lung cancer patients (874 patients) with 633 low-expression patients and 241 high-expression patients with a cut-off value for the gene expression of 756.1. This evidence concerns the gene RPL39L and lung carcinoma.